NCT02073500
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Recruiting · Not specified · Oslo University Hospital · registry updated 2021-07-28
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
Inclusion
- age \> 18 years
- confirmed diagnosis of peritoneal surface malignancy
- candidate for CRS-HIPEC
- written informed consent
Exclusion
- Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.